Plasma mediators in patients with severe COVID-19 cause lung endothelial barrier failure
Open Access
- 5 November 2020
- journal article
- letter
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 57 (3), 2002384
- https://doi.org/10.1183/13993003.02384-2020
Abstract
Plasma of COVID-19 patients induces pulmonary microvascular barrier failure which increases with disease severity. Here, we report a versatile high-throughput screening platform to test for involved plasma mediators and the therapeutic potential of barrier stabilising compounds.Funding Information
- Berlin University Alliance (Corona Virus Pre Exploration Project, PreEP Corona)
- Charité Universitätsmedizin Berlin
- Bundesministerium für Bildung und Forschung (CAPSyS-FKZ, PROVID, Phage4Cure-FKZ, RAPID, SYMPATH, alvBarriere-COVID-19)
- Canadian Institutes of Health Research
- Charité-Zeiss MultiDim
- Deutsches Zentrum für Herz-Kreislaufforschung
- Berlin Institute of Health
- Deutsche Forschungsgemeinschaft (1218/11-1, 1218/9-1, SFB-TR84)
This publication has 5 references indexed in Scilit:
- Ultra-High-Throughput Clinical Proteomics Reveals Classifiers of COVID-19 InfectionCell Systems, 2020
- Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19The New England Journal of Medicine, 2020
- Urgent reconsideration of lung edema as a preventable outcome in COVID-19: inhibition of TRPV4 represents a promising and feasible approachAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2020
- Pathological findings of COVID-19 associated with acute respiratory distress syndromeThe Lancet Respiratory Medicine, 2020
- Exploring the pathogenesis of severe acute respiratory syndrome (SARS): the tissue distribution of the coronavirus (SARS‐CoV) and its putative receptor, angiotensin‐converting enzyme 2 (ACE2)The Journal of Pathology, 2004